Tau PET in tauopathies: a systematic review and meta-analysis of regional tau deposition and diagnostic performance

Background Tauopathies represent a diverse group of neurodegenerative diseases characterized by abnormal tau protein aggregation. Accurate differential diagnosis remains challenging due to overlapping clinical features and the limited specificity of conventional imaging. Tau positron emission tomography (PET) imaging represents a promising diagnostic tool for tauopathies. This systematic review and meta-analysis aimed to examine regional uptake patterns and assess the diagnostic performance of tau PET across major tauopathies. Methods A systematic review and meta-analysis were conducted to evaluate regional tau deposition and the diagnostic performance of tau PET. Regional tau tracer uptake values and diagnostic accuracy parameters (sensitivity, specificity, and area under the curve [AUC]) were analyzed using random effects models to estimate standardized mean differences (SMD) and pooled diagnostic performance, respectively. Results Compared with HCs, patients with Alzheimer's disease (AD) had significantly elevated tau uptake in 27 brain regions (SMD range: 0.39–2.58; p < 0.01), patients with progressive supranuclear palsy (PSP) in eight regions (0.41–1.71; p < 0.05), and patients with corticobasal syndrome (CBS) in four regions (1.06–1.86; p < 0.01). The pooled AUCs for distinguishing AD, PSP, and AD/mild cognitive impairment (MCI) patients from HCs were 0.92 (95% CI: 0.89–0.96), 0.92 (0.85–0.99), and 0.84 (0.74–0.94), respectively. Subgroup analyses revealed differences in tau uptake and diagnostic accuracy by outcome type, atlas application, tracer type, and generation. Conclusions Our findings demonstrate that tau PET reveals disease-specific uptake patterns with high diagnostic accuracy across tauopathies. The distinct spatial distributions of AD, PSP, and CBS provide valuable neuroimaging signatures for differential diagnosis. These results support the use of tau PET as a promising clinical biomarker, although methodological standardization is essential for optimal implementation.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11552225/v1
Primary Topic
Dementia and Cognitive Impairment Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Tau PET in tauopathies: a systematic review and meta-analysis of regional tau deposition and diagnostic performance

Axel Rominger, Chuantao Zuo, Ruiqing Ni, Jingjie Ge et al.
Research Square
Dementia and Cognitive Impairment Research
preprint

Tau PET in tauopathies: a systematic review and meta-analysis of regional tau deposition and diagnostic performance

Axel Rominger, Chuantao Zuo, Ruiqing Ni, Jingjie Ge, Jiaying Lu, Liu Yang, Quanling Jiang, Huamei Lin, Jing Wang
preprint en

Abstract

Background Tauopathies represent a diverse group of neurodegenerative diseases characterized by abnormal tau protein aggregation. Accurate differential diagnosis remains challenging due to overlapping clinical features and the limited specificity of conventional imaging. Tau positron emission tomography (PET) imaging represents a promising diagnostic tool for tauopathies. This systematic review and meta-analysis aimed to examine regional uptake patterns and assess the diagnostic performance of tau PET across major tauopathies. Methods A systematic review and meta-analysis were conducted to evaluate regional tau deposition and the diagnostic performance of tau PET. Regional tau tracer uptake values and diagnostic accuracy parameters (sensitivity, specificity, and area under the curve [AUC]) were analyzed using random effects models to estimate standardized mean differences (SMD) and pooled diagnostic performance, respectively. Results Compared with HCs, patients with Alzheimer's disease (AD) had significantly elevated tau uptake in 27 brain regions (SMD range: 0.39–2.58; p < 0.01), patients with progressive supranuclear palsy (PSP) in eight regions (0.41–1.71; p < 0.05), and patients with corticobasal syndrome (CBS) in four regions (1.06–1.86; p < 0.01). The pooled AUCs for distinguishing AD, PSP, and AD/mild cognitive impairment (MCI) patients from HCs were 0.92 (95% CI: 0.89–0.96), 0.92 (0.85–0.99), and 0.84 (0.74–0.94), respectively. Subgroup analyses revealed differences in tau uptake and diagnostic accuracy by outcome type, atlas application, tracer type, and generation. Conclusions Our findings demonstrate that tau PET reveals disease-specific uptake patterns with high diagnostic accuracy across tauopathies. The distinct spatial distributions of AD, PSP, and CBS provide valuable neuroimaging signatures for differential diagnosis. These results support the use of tau PET as a promising clinical biomarker, although methodological standardization is essential for optimal implementation.

Research Square
University of Bern (CH), University Hospital of Bern (CH), Huashan Hospital (CN)
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon